User login
Key clinical point: Absence of cutaneous allodynia was a predictor of treatment response following withdrawal therapy in patients with chronic migraine and medication overuse, with the predictive value being even more pronounced when compared with cephalic or extracephalic allodynia.
Major finding: The chances of reversion from chronic to episodic migraine were ~2.5 times higher in patients without vs with cutaneous allodynia (odds ratio [OR] 2.45; P = .042), with the predictive values of absence of allodynia being even more pronounced when compared with patients having cephalic (OR 4.16; P = .024) or extracephalic (OR 7.32; P = .003) allodynia.
Study details: This study, conducted as part of the Chronification And Reversibility of Migraine study, included 173 patients with chronic migraine and medication overuse, of whom 129 had cutaneous allodynia.
Disclosures: This study was supported by grants from the Netherlands Organization for Scientific Research and the Dutch Brain Foundation. I de Boer and GM Terwindt declared receiving independent support, consultancy support, or both from various sources.
Source: Pijpers JA et al. Cutaneous allodynia as predictor for treatment response in chronic migraine: A cohort study. J Headache Pain. 2023;24:118 (Aug 30). Doi: 10.1186/s10194-023-01651-9.
Key clinical point: Absence of cutaneous allodynia was a predictor of treatment response following withdrawal therapy in patients with chronic migraine and medication overuse, with the predictive value being even more pronounced when compared with cephalic or extracephalic allodynia.
Major finding: The chances of reversion from chronic to episodic migraine were ~2.5 times higher in patients without vs with cutaneous allodynia (odds ratio [OR] 2.45; P = .042), with the predictive values of absence of allodynia being even more pronounced when compared with patients having cephalic (OR 4.16; P = .024) or extracephalic (OR 7.32; P = .003) allodynia.
Study details: This study, conducted as part of the Chronification And Reversibility of Migraine study, included 173 patients with chronic migraine and medication overuse, of whom 129 had cutaneous allodynia.
Disclosures: This study was supported by grants from the Netherlands Organization for Scientific Research and the Dutch Brain Foundation. I de Boer and GM Terwindt declared receiving independent support, consultancy support, or both from various sources.
Source: Pijpers JA et al. Cutaneous allodynia as predictor for treatment response in chronic migraine: A cohort study. J Headache Pain. 2023;24:118 (Aug 30). Doi: 10.1186/s10194-023-01651-9.
Key clinical point: Absence of cutaneous allodynia was a predictor of treatment response following withdrawal therapy in patients with chronic migraine and medication overuse, with the predictive value being even more pronounced when compared with cephalic or extracephalic allodynia.
Major finding: The chances of reversion from chronic to episodic migraine were ~2.5 times higher in patients without vs with cutaneous allodynia (odds ratio [OR] 2.45; P = .042), with the predictive values of absence of allodynia being even more pronounced when compared with patients having cephalic (OR 4.16; P = .024) or extracephalic (OR 7.32; P = .003) allodynia.
Study details: This study, conducted as part of the Chronification And Reversibility of Migraine study, included 173 patients with chronic migraine and medication overuse, of whom 129 had cutaneous allodynia.
Disclosures: This study was supported by grants from the Netherlands Organization for Scientific Research and the Dutch Brain Foundation. I de Boer and GM Terwindt declared receiving independent support, consultancy support, or both from various sources.
Source: Pijpers JA et al. Cutaneous allodynia as predictor for treatment response in chronic migraine: A cohort study. J Headache Pain. 2023;24:118 (Aug 30). Doi: 10.1186/s10194-023-01651-9.